The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

we are focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood refractory chronic cough or rarer conditions like systemic sclerosis ...

If approved, the monoclonal antibody is expected to become the initial monthly-dosed biologic for COPD. GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

GSK said that if approved, Nucala could be the first biologic with monthly dosing for patients with COPD, which affects more than 390 million people globally and over 40 million people in Europe.

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...